232 related articles for article (PubMed ID: 30535885)
21. Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study.
Haifer C; Srinivasan A; An YK; Picardo S; van Langenberg D; Menon S; Begun J; Ghaly S; Thin L
Med J Aust; 2021 Feb; 214(3):128-133. PubMed ID: 33070332
[TBL] [Abstract][Full Text] [Related]
22. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.
Razanskaite V; Bettey M; Downey L; Wright J; Callaghan J; Rush M; Whiteoak S; Ker S; Perry K; Underhill C; Efrem E; Ahmed I; Cummings F
J Crohns Colitis; 2017 Jun; 11(6):690-696. PubMed ID: 28130330
[TBL] [Abstract][Full Text] [Related]
23. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea.
Park SH; Kim YH; Lee JH; Kwon HJ; Lee SH; Park DI; Kim HK; Cheon JH; Im JP; Kim YS; Lee SY; Lee SJ
Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():35-44. PubMed ID: 26395533
[TBL] [Abstract][Full Text] [Related]
24. Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months.
Guerra Veloz MF; Vázquez Morón JM; Belvis Jiménez M; Pallarés Manrique H; Valdés Delgado T; Castro Laria L; Maldonado Pérez B; Benítez Roldán A; Perea Amarillo R; Merino V; Caunedo Álvarez Á; Argüelles Arias F
Rev Esp Enferm Dig; 2018 Sep; 110(9):564-570. PubMed ID: 29893581
[TBL] [Abstract][Full Text] [Related]
25. Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.
Eberl A; Huoponen S; Pahikkala T; Blom M; Arkkila P; Sipponen T
Scand J Gastroenterol; 2017 Dec; 52(12):1348-1353. PubMed ID: 28838273
[TBL] [Abstract][Full Text] [Related]
26. Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease.
Schreiber S; Ben-Horin S; Leszczyszyn J; Dudkowiak R; Lahat A; Gawdis-Wojnarska B; Pukitis A; Horynski M; Farkas K; Kierkus J; Kowalski M; Lee SJ; Kim SH; Suh JH; Kim MR; Lee SG; Ye BD; Reinisch W
Gastroenterology; 2021 Jun; 160(7):2340-2353. PubMed ID: 33676969
[TBL] [Abstract][Full Text] [Related]
27. Long-term effectiveness and pharmacokinetics of the infliximab biosimilar CT-P13 after switching from the originator during the treatment of inflammatory bowel disease.
Martín-Gutiérrez N; Sánchez-Hernández JG; Rebollo N; Pordomingo AF; Muñoz F; Otero MJ
Eur J Hosp Pharm; 2022 Jul; 29(4):222-227. PubMed ID: 33115797
[TBL] [Abstract][Full Text] [Related]
28. Outcomes of Patients With Inflammatory Bowel Diseases Switched From Maintenance Therapy With a Biosimilar to Remicade.
Ilias A; Szanto K; Gonczi L; Kurti Z; Golovics PA; Farkas K; Schafer E; Szepes Z; Szalay B; Vincze A; Szamosi T; Molnar T; Lakatos PL
Clin Gastroenterol Hepatol; 2019 Nov; 17(12):2506-2513.e2. PubMed ID: 30630103
[TBL] [Abstract][Full Text] [Related]
29. Efficacious transition from reference infliximab to biosimilar infliximab in clinical practice.
Layegh Z; Ruwaard J; Hebing RCF; L' Ami MJ; van der Weele W; Nurmohamed MT; Krieckaert C; Wolbink G
Int J Rheum Dis; 2019 May; 22(5):869-873. PubMed ID: 30767391
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience.
Ratnakumaran R; To N; Gracie DJ; Selinger CP; O'Connor A; Clark T; Carey N; Leigh K; Bourner L; Ford AC; Hamlin PJ
Scand J Gastroenterol; 2018 Jun; 53(6):700-707. PubMed ID: 29687730
[TBL] [Abstract][Full Text] [Related]
31. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data.
Nikiphorou E; Kautiainen H; Hannonen P; Asikainen J; Kokko A; Rannio T; Sokka T
Expert Opin Biol Ther; 2015; 15(12):1677-83. PubMed ID: 26549204
[TBL] [Abstract][Full Text] [Related]
32. Infliximab biosimilar CT-P13 therapy is effective and safe in maintaining remission in Crohn's disease and ulcerative colitis - experiences from a single center.
Farkas K; Rutka M; Ferenci T; Nagy F; Bálint A; Bor R; Milassin Á; Fábián A; Szántó K; Végh Z; Kürti Z; Lakatos PL; Szepes Z; Molnár T
Expert Opin Biol Ther; 2017 Nov; 17(11):1325-1332. PubMed ID: 28819991
[TBL] [Abstract][Full Text] [Related]
33. The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar.
Fiorino G; Manetti N; Armuzzi A; Orlando A; Variola A; Bonovas S; Bossa F; Maconi G; DʼIncà R; Lionetti P; Cantoro L; Fries W; Annunziata ML; Costa F; Terpin MM; Biancone L; Cortelezzi CC; Amato A; Ardizzone S; Danese S; Guidi L; Rizzuto G; Massella A; Andriulli A; Massari A; Lorenzon G; Ghione S; Kohn A; Ventra A; Annese V;
Inflamm Bowel Dis; 2017 Feb; 23(2):233-243. PubMed ID: 28092307
[TBL] [Abstract][Full Text] [Related]
34. Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort.
Gros B; Plevris N; Constantine-Cooke N; Lyons M; O'Hare C; Noble C; Arnott ID; Jones GR; Lees CW; Derikx LAAP
United European Gastroenterol J; 2023 Mar; 11(2):179-188. PubMed ID: 36802176
[TBL] [Abstract][Full Text] [Related]
35. Real-world observational cohort study of treatment patterns and safety outcomes of infliximab biosimilar CT-P13 for the treatment of inflammatory bowel disease (CONNECT-IBD).
Bokemeyer B; Hlavaty T; Allez M; Selema P; Moosavi S; Cadatal MJ; Fowler H; Mueller M; Liau KF; Gisbert JP
Expert Opin Biol Ther; 2023; 23(8):791-800. PubMed ID: 37038897
[TBL] [Abstract][Full Text] [Related]
36. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.
Jørgensen KK; Olsen IC; Goll GL; Lorentzen M; Bolstad N; Haavardsholm EA; Lundin KEA; Mørk C; Jahnsen J; Kvien TK;
Lancet; 2017 Jun; 389(10086):2304-2316. PubMed ID: 28502609
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness and Safety of Switching from Innovator Infliximab to Biosimilar CT-P13 in Inflammatory Rheumatic Diseases: A Real-World Case Study.
Vergara-Dangond C; Sáez Belló M; Climente Martí M; Llopis Salvia P; Alegre-Sancho JJ
Drugs R D; 2017 Sep; 17(3):481-485. PubMed ID: 28667384
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months.
Argüelles-Arias F; Guerra Veloz MF; Perea Amarillo R; Vilches-Arenas A; Castro Laria L; Maldonado Pérez B; Chaaro D; Benítez Roldán A; Merino V; Ramírez G; Caunedo Álvarez A; Romero Gómez M
Dig Dis Sci; 2017 May; 62(5):1305-1312. PubMed ID: 28281165
[TBL] [Abstract][Full Text] [Related]
39. Experience with Biosimilar Infliximab (Remsima®) in Norway.
Jahnsen J; Kaasen Jørgensen K
Dig Dis; 2017; 35(1-2):83-90. PubMed ID: 28147374
[TBL] [Abstract][Full Text] [Related]
40. Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases.
Blair HA; Deeks ED
BioDrugs; 2016 Oct; 30(5):469-480. PubMed ID: 27650650
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]